OCRELIZUMAB (Ocrevus) prior authorization at Blue Cross Blue Shield of Massachusetts
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross Blue Shield of Massachusetts requires CD20-directed Cytolytic Antibody prior-authorization documentation for OCRELIZUMAB (Ocrevus): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross Blue Shield of Massachusetts reviews OCRELIZUMAB (Ocrevus) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody. Blue Cross Blue Shield of Massachusetts-specific context: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Massachusetts's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- MA-specific mandated benefit disputes (most generous in US)
- Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
- Tiered-network provider disputes
- Specialty drug PA
OCRELIZUMAB (Ocrevus)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Site-of-care reduction (home infusion vs hospital)
- Step therapy
Brand: Ocrevus. First FDA-approved DMT for primary progressive MS.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Blue Cross Blue Shield of Massachusetts denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://provider.bluecrossma.com) with the same packet plus an applicable, current clinical source supporting OCRELIZUMAB (Ocrevus)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross Blue Shield of Massachusetts denial on DenialHelp.
Contact Blue Cross Blue Shield of Massachusetts
- Provider portal: https://provider.bluecrossma.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Massachusetts need for OCRELIZUMAB (Ocrevus) prior auth?
Blue Cross Blue Shield of Massachusetts's typical PA packet for OCRELIZUMAB (Ocrevus): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross Blue Shield of Massachusetts?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OCRELIZUMAB (Ocrevus) at Blue Cross Blue Shield of Massachusetts?
Preparation scenarios to check against the current notice and policy include: MA-specific mandated benefit disputes (most generous in US); Behavioral health parity (MA has tighter parity rules than federal MHPAEA); Tiered-network provider disputes. These are not measured frequency claims. For OCRELIZUMAB (Ocrevus), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Massachusetts on OCRELIZUMAB (Ocrevus)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Blue Cross Blue Shield of Massachusetts
- Aflibercept at Blue Cross Blue Shield of Massachusetts
- Apixaban at Blue Cross Blue Shield of Massachusetts
- Atezolizumab at Blue Cross Blue Shield of Massachusetts
- OCRELIZUMAB (Ocrevus) at UnitedHealthcare
- OCRELIZUMAB (Ocrevus) at Elevance Health
- OCRELIZUMAB (Ocrevus) at Aetna
Generate the OCRELIZUMAB (Ocrevus) PA packet
Open ApprovalHelp — generate a OCRELIZUMAB (Ocrevus) prior-auth packet tailored to Blue Cross Blue Shield of Massachusetts's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com